Associated Papers
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Schram AM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.
Kato T et al.
British Journal of Cancer, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors.
Kaczorowski M et al.
The Journal of Pathology. Clinical Research, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Richters L et al.
Jama Network Open, 2025
Classification of PTEN germline non-truncating variants: a new approach to interpretation.
Margot H et al.
Journal of Medical Genetics, 2024
Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases.
Jitpasutham T et al.
Cancer Cytopathology, 2024
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.
Serebriiskii IG et al.
Nature Communications, 2022
Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development.
Park VS et al.
Nar Cancer, 2022
Distinguishing between PTEN clinical phenotypes through mutation analysis.
Portelli S et al.
Computational and Structural Biotechnology Journal, 2021
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C et al.
International Journal of Cancer, 2020
Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Akahane T et al.
Bmc Medical Genomics, 2020
Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies.
Palumbo E et al.
Journal of Biomolecular Structure & Dynamics, 2020
Predicting the Disease Risk of Protein Mutation Sequences With Pre-training Model.
Li K et al.
Frontiers in Genetics, 2020
A pathogenic role for germline PTEN variants which accumulate into the nucleus.
Mingo J et al.
European Journal of Human Genetics : Ejhg, 2018
Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
Pelttari LM et al.
Clinical Genetics, 2018
Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
Jauhri M et al.
Medical Oncology (northwood, London, England), 2016
Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.
Spinelli L et al.
Journal of Medical Genetics, 2015
A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer.
Pradella LM et al.
Bmc Cancer, 2014
High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
Bubien V et al.
Journal of Medical Genetics, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2012
Challenges in the management of a patient with Cowden syndrome: case report and literature review.
Melbārde-Gorkuša I et al.
Hereditary Cancer in Clinical Practice, 2012
Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
Pilarski R et al.
Journal of Medical Genetics, 2011
Somatic mutations are present in all members of the AKT family in endometrial carcinoma.
Dutt A et al.
British Journal of Cancer, 2009
A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.
Denning G et al.
Oncogene, 2007
Genetic screening for hereditary diffuse gastric cancer.
Oliveira C et al.
Expert Review of Molecular Diagnostics, 2003
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K et al.
The American Journal of Pathology, 2001
Identification of PTEN mutations in five families with Bannayan-Zonana syndrome.
Tok Celebi J et al.
Experimental Dermatology, 1999
Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation.
Sathornsumetee S et al.
Neuro-oncology Advances, 0